Therapie — Behandlung früher und heute (Stufenplan)

  • R. Dietz
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Patienten mit schwerer Herzinsuffizienz leiden in erster Linie unter einer Einschränkung ihrer Lebensqualität infolge ihrer geringen Belastbarkeit und der peripheren Ödeme. Erstes Ziel bei der medikamentösen Behandlung der Herzinsuffizienz ist demnach die Verbesserung der Lebensqualität. Dabei kann im Einzelfall sowohl der Arzt als auch der betroffene Patient relativ leicht entscheiden, ob der eingeschlagene Weg der medikamentösen Behandlung erfolgreich ist. Schwieriger und im Einzelfall unmöglich ist es, zu entscheiden, ob es mit der medikamentösen Behandlung gelingt, auch die Lebenserwartung zu verbessern. Die Beantwortung dieser Frage ist nur mit Hilfe von großen randomisierten Studien möglich. Ein weiteres Ziel bei der Behandlung der Herzinsuffizienz sollte in Zukunft auch die frühzeitige Beeinflussung von Faktoren sein, die zu einer Progression der Herzinsuffizienz bereits in frühen Stadien führen, um so deletäre Folgen einer ungünstigen Entwicklung aufzuhalten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bayliss J, Canepa-Anson R, Norell MS, Poole-Wilson P, Sutton G (1986) Vasodilatation with Captopril and prazosin in chronic heart failure: Double bünd study at rest and on exercise. Br Heart J 55:265–273PubMedCrossRefGoogle Scholar
  2. Bigger JT, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ (1985) Effect of digital treatment on survival after acute myocardial infarction. Am J Cardiol 55:623–630PubMedCrossRefGoogle Scholar
  3. Braunwald E (1985) Effects of digitalis on the normal and the failing heart. J Am Coll Cardiol 5:51A-59APubMedCrossRefGoogle Scholar
  4. Braunwald E (1988) Heart disease. A textbook of cardiovascular medicine, Saunders, PhiladelphiaGoogle Scholar
  5. Byington R, Goldstein S, For The BHAT Research Group (1985) Association of digitalis therapy with mortality in survivors of acute myocardial infarction: Observations in the beta-blocker heart attac trial. J Am Coll Cardiol 6:976–982PubMedCrossRefGoogle Scholar
  6. Captopril Multicenter Research Group (1988) Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure. JAMA 259:539–544CrossRefGoogle Scholar
  7. Cody RJ (1984) Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. Am J Med 772A:71–77Google Scholar
  8. Cohn JN (1984) Unloading the heart in congestive heart failure. Am J Med 77 [Suppl 2 A]:67–70PubMedGoogle Scholar
  9. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J med 314:1547–1552Google Scholar
  10. Colucci WS, Wilhams GH, Alexander RW, Braunwald E (1981) Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. Am J Med 71:89–99PubMedCrossRefGoogle Scholar
  11. Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429–1435CrossRefGoogle Scholar
  12. Dargie HJ, Cleland JGF, Leckie BJ (1987) Relations of arrhythmias and electrolyte in patients with severe chronic heart failure. Circulation 75:98–107Google Scholar
  13. Fleg JL, Gottlieb SH, Lakatta EG 1982) Is digoxin really important in treatment of compensated heart failure? Am J Med 73:244–250PubMedCrossRefGoogle Scholar
  14. Franciosa JA, Jordan RA, Wilen MM, Leddy CL (1984) Minoxidil in patients with chronic left heart failure: Contrasting hemodynamic and clinical effects in a controlled trial. Circulation 70:63–68PubMedCrossRefGoogle Scholar
  15. Franciosa JA, Weber KT, Levine TB et al. (1982) Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placebo. Am Heart J 104:587–594PubMedCrossRefGoogle Scholar
  16. Gheorghiade M, Beller GA (1983) Effects of discontinuing maintenance dogoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol 51:1243–1250PubMedCrossRefGoogle Scholar
  17. Johnston GD, McDevitt DG (1979) Is maintenance digoxin necessary in patients with sinus rhythm? Lancet 8116:567–570CrossRefGoogle Scholar
  18. Katz AM (1986) Potential Deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73:184–190Google Scholar
  19. Krell MJ, Kline EM, Bates ER et al. (1986) Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 112:787–791PubMedCrossRefGoogle Scholar
  20. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M and for the Amrinone Multicenter Trial Group (1985) Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 71:963–971PubMedCrossRefGoogle Scholar
  21. Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez G (1988) Relative Efficacy of vasodilator therapy in chronic congestive heart failure. JAMA 259:3422–3426PubMedCrossRefGoogle Scholar
  22. Müller JE, Turi ZG, Stone PH et al. and the MILIS Study. Group (1986) Digoxin therapy and mortality after myocardial infarction; Experience in the MILIS Study. N Engl J Med 314:265–271PubMedCrossRefGoogle Scholar
  23. Packer M (1983) Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepicism. J Am Coll Cardiol 2:841–852PubMedCrossRefGoogle Scholar
  24. Packer M (1984) Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Am J Med [Suppl. 6A]:3–13Google Scholar
  25. Packer M, LeJemtel TH (1982) Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure. Prog Cardiovasc Dis 24:275–293PubMedCrossRefGoogle Scholar
  26. Packer M, Medina N, Yushak M (1984 a) Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 100:782–789Google Scholar
  27. Packer M, Medina N, Yushak M (1984b) Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70:1038–1047PubMedCrossRefGoogle Scholar
  28. Packer M, Meiler J, Gorlin R, Herman MV (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59:531–539PubMedGoogle Scholar
  29. Ryan TJ, Baüey KR, McCabe CH, Luk S, Fisher LD, Mock MB, Killip T (1983) The effects of digitalis on survival in high-risk patients with coronary artery disease; the Coronary Artery Surgery Study (CASS). Circulation 67:735–742PubMedCrossRefGoogle Scholar
  30. Sullivan MJ, Higginbotham MB, Cobb FR (1988) Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation 78:506–518PubMedCrossRefGoogle Scholar
  31. Taylor SH, Silke B, Nelson GJC (1982) Principles of treatment of left ventricular failure. Eur Heart J 3:19–43PubMedGoogle Scholar
  32. Yusuf S, Wittes J, Bailey K, Furberg C (1986) Digitalis a new controversy regarding an old drug. Circulation 73:14–18PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Dietz

There are no affiliations available

Personalised recommendations